Mesoblast Ltd (ASX:MSB) is a leader in providing allogeneic (off the shelf) cellular medicines. It owns a portfolio of late-stage product candidates with three product candidates in Phase 3 trials, being acute graft versus host disease, chronic heart failure and chronic low back pain due to degenerative disc disease. The company has facilities in Melbourne, New York, Singapore and Texas and is listed on the ASX and the NASDAQ.
The Mesoblast Limited (ASX:MSB) share price is up more than 6% after announcing that it has won an award.
Mesoblast Limited (ASX:MSB) shares dropped 3% on Friday after announcing news relating to COVID-19 patients.
The Mesoblast Limited (ASX:MSB) share price has soared 38% higher after the biotech business announced positive US news.
The Mesoblast Limited (ASX: MSB) share price has taken a dive today after the company’s quest to obtain FDA approval for its lead drug candidate hit a speed bump.
The S&P/ASX 200 (ASX: XJO) and the broader Australian share market is expected to open higher on Monday morning, with the Sydney Futures Exchange pointing to a positive open of 82 points.
Shares in Mesoblast Limited (ASX:MSB) fell as much as 10% this morning after the company successfully completed a $75 million capital raising.
Shares in Mesoblast Limited (ASX:MSB) have soared more than 30% in just over 24 hours following yesterday’s announcement of a strategic partnership with a German pharmaceutical business.
The ASX 200 (INDEXASX:XJO)(^AXJO) is expected to open higher today, the USA’s S&P 500 Index (.INX) rose by 1.27% on Thursday.
The Mesoblast Limited (ASX:MSB) share price is down around 2.5% after announcing its March 2019 update.
